Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Phase 4
Completed
NCT05590585
| Condition | Moderate-to-Severe Atopic Dermatitis, Atopic Eczema |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | Regeneron Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 124 participants |
|---|
| Interventions | dupilumab, Topical emollient (moisturizer) |
|---|
| Start date | Jan 11, 2023 |
|---|
| Completion date | Nov 14, 2024 |
|---|
| Results posted | Jan 2, 2026 |
|---|
Summary
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in your blood at different times * How much the study drug improves quality of life and mental health
Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)
Week 24 · percentage of participants
| Dupilumab | 76.0 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.